Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

Milvexian’s failure in acute coronary syndrome dampens the outlook for other anticoagulants like it and is the latest in a ...

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...

The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...

The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of ...

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.

Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero." ...